Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of alzheimer’s disease: a focus on aducanumab and lecanemab

HIGHLIGHTS

• who: Feiqi Zhu and Jie Zhu from the Department of Neurology, Neuroscience Center, The First Hospital of Jilin University, Changchun, China, Cognitive have published the research: Impact of Anti-amyloid-u03b2 Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimeru2019s Disease: A Focus on Aducanumab and Lecanemab, in the Journal: (JOURNAL)
• what: In the review, the authors discussed the effects of mabs, including aducanumab, bapineuzumab, gantenerumab, solanezumab, and lecanemab on AD, especially the concentration on the impacts of aducanumab and lecanemab on AD pathology and clinical manifestations.
• how: The therapeutic and side . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.